Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance
Completed · Not applicable · Has a placebo group
Conditions studied: Healthy Volunteers
In brief
In recent years, there has been increased focus on cognitive side effects of sleep-inducing medications that may contribute to unusual behavior during unexpected awakenings during the night. Concerns regarding these side effects have led to a class Food and Drug Administration (FDA) warning for all sleep-inducing medications. Almorexant is an experimental sleep-inducing medication in a new class of medications that is being extensively developed by multiple pharmaceutical companies. Medications in this class block wake/arousal centers in the brain that function with proteins called hypocretins. The goal of this study is to evaluate the impact on cognitive performance of almorexant vs. zolpidem (an approved sleep aid) or placebo.
Key facts
- Study ID
- NCT01243060
- Run by
- Northern California Institute of Research and Education
- People needed
- 203
- Starts
- 2011-05-01
- Expected to finish
- 2014-07-01
- Last updated by the study team
- 2014-10-06
Who can join
Age: 19 and older, up to 39. Sex: any. Healthy volunteers: accepted.
Where it is running
- San Francisco Veterans Affairs Medical Center — San Francisco, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.